Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer.

Trial Profile

Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs Carboplatin (Primary) ; Irinotecan (Primary) ; Sunitinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Planned End Date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 04 Jan 2012 Planned end date changed from 1 Oct 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top